Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Howarth

Showing results (51-60 of 107) with videos related to

Pageof 11
Sort By:
The Journal of Allergy and Clinical Immunology|April 22, 2008
Epigenetic mechanisms silence a disintegrin and metalloprotease 33 expression in bronchial epithelial cellsYouwen Yang, Hans Michael Haitchi, Julie Cakebread, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2023
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A AnalysisMark C Liu, Diego Bagnasco, Andrea Matucci, et al.
Lancet (London, England)|August 28, 2015
Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological dataTimothy Hinks, Xiaoying Zhou, Karl Staples, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 2, 2021
Clinical evaluation of type 2 disease status in a real-world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil countsAdnan Azim, Colin Newell, Clair Barber, et al.
Journal of Patient-Reported Outcomes|January 20, 2023
Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE studyWytske Fokkens, Andrew Trigg, Stella E Lee, et al.
The European Respiratory Journal|January 8, 2022
Vulnerability to acid reflux of the airway epithelium in severe asthmaJeanne-Marie Perotin, Gabrielle Wheway, Kamran Tariq, et al.
Allergy, Asthma & Immunology Research|July 30, 2025
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A <i>Post-hoc</i> Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled TrialRuchong Chen, Yuanrong Dai, Danrong Yang, et al.
Advances in Therapy|December 24, 2025
Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAINJohn Oppenheimer, Ian D Pavord, Tom Corbridge, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 22, 2026
Depemokimab reduces asthma exacerbations similarly to other biologics: systematic trial review and indirect treatment comparisonArnaud Bourdin, Ian D Pavord, Nicholas Ballew, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 13, 2025
Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthmaJason K Lee, Stephen J Pollard, Mark C Liu, et al.
Pageof 11

Showing results (51-60 of 107) with videos related to

Sort By:
Pageof 11
The Journal of Allergy and Clinical Immunology|April 22, 2008
Epigenetic mechanisms silence a disintegrin and metalloprotease 33 expression in bronchial epithelial cellsYouwen Yang, Hans Michael Haitchi, Julie Cakebread, et al.
The Journal of Allergy and Clinical Immunology. in Practice|July 28, 2023
Mepolizumab in Patients With Severe Asthma and Comorbidities: 1-Year REALITI-A AnalysisMark C Liu, Diego Bagnasco, Andrea Matucci, et al.
Lancet (London, England)|August 28, 2015
Multidimensional endotypes of asthma: topological data analysis of cross-sectional clinical, pathological, and immunological dataTimothy Hinks, Xiaoying Zhou, Karl Staples, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|February 2, 2021
Clinical evaluation of type 2 disease status in a real-world population of difficult to manage asthma using historic electronic healthcare records of blood eosinophil countsAdnan Azim, Colin Newell, Clair Barber, et al.
Journal of Patient-Reported Outcomes|January 20, 2023
Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE studyWytske Fokkens, Andrew Trigg, Stella E Lee, et al.
The European Respiratory Journal|January 8, 2022
Vulnerability to acid reflux of the airway epithelium in severe asthmaJeanne-Marie Perotin, Gabrielle Wheway, Kamran Tariq, et al.
Allergy, Asthma & Immunology Research|July 30, 2025
Clinical Remission Outcome in Chinese Patients With Severe Asthma With an Eosinophilic Phenotype Receiving Mepolizumab: A <i>Post-hoc</i> Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled TrialRuchong Chen, Yuanrong Dai, Danrong Yang, et al.
Advances in Therapy|December 24, 2025
Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAINJohn Oppenheimer, Ian D Pavord, Tom Corbridge, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 22, 2026
Depemokimab reduces asthma exacerbations similarly to other biologics: systematic trial review and indirect treatment comparisonArnaud Bourdin, Ian D Pavord, Nicholas Ballew, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 13, 2025
Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthmaJason K Lee, Stephen J Pollard, Mark C Liu, et al.
Pageof 11